(99m)Tc-radiolabelled peptides for tumour imaging: present and future.
Receptor-binding peptides have attracted an enormous interest in targeting molecules for the development of tumour specific radiopharmaceutical compounds. The overexpression of many receptors on human tumour makes such peptide-ligands attractive agents for diagnostic imaging and therapy of cancers. The use of solid-phase peptide synthesis and the availability of a wide range of bifunctional chelating agents for the radiolabelling of bioactive peptides with radionuclides have produced a wide variety of useful radiopharmaceutical molecules. For diagnostic purposes, techenetium - 99m is the ideal radionuclide thanks to its nuclear properties and the availability of a low cost portable generator system.
Bolzati
C
C
Institute of Biomolecular Chemistry of CNR, Padova Unit, via Marzolo 1, 35131 Padova, Italy. bolzati@icis.cnr.it
Refosco
F
F
Marchiani
A
A
Ruzza
P
P
D003952:Diagnostic Imaging / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis*; D019275:Radiopharmaceuticals; D013667:Technetium
D019275:Radiopharmaceuticals; D013667:Technetium